These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21421243)

  • 1. Re: Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. K. E. Hoffman, P. L. Nguyen, A. K. Ng and A. V. D'Amico. J Urol 2010; 183: 1798-1802.
    Neulander EZ
    J Urol; 2011 May; 185(5):1982; author reply 1983. PubMed ID: 21421243
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
    Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
    J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer among men 75 years of age or older.
    Barry MJ
    N Engl J Med; 2008 Dec; 359(24):2515-6. PubMed ID: 19073973
    [No Abstract]   [Full Text] [Related]  

  • 5. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
    Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
    CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should men over the age of 65 years receive PSA screening? Argument in favor.
    Whitson JM; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):230-1. PubMed ID: 18349861
    [No Abstract]   [Full Text] [Related]  

  • 7. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
    Kwiatkowski M; Klotz L; Hugosson J; Recker F
    Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762
    [No Abstract]   [Full Text] [Related]  

  • 13. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prostate cancer screening among health fair participants.
    Chiu BC; Anderson JR; Corbin D
    Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 16. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
    Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
    Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass screening for prostate cancer in Korea: a population based study.
    Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
    J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral associations between prostate and colon cancer screening.
    Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
    J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.